<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04474210</url>
  </required_header>
  <id_info>
    <org_study_id>CR108802</org_study_id>
    <secondary_id>56136379HPB1010</secondary_id>
    <nct_id>NCT04474210</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-56136379 in Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of
      JNJ-56136379 in adult participants with renal impairment compared with healthy participants
      with normal renal function.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">February 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Analyte Concentration (Cmax)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Cmax is defined as the maximum observed plasma analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Tmax is defined as the actual sampling time to reach the maximum observed plasma analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Analyte Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC [0-24])</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
    <description>AUC (0-24) is defined as area under the analyte concentration-time curve (AUC) from time 0 to 24 hours postdose, calculated by linear-linear trapezoidal summation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Analyte Concentration-time Curve From Time Zero to 144 Hours Postdose (AUC [0-144])</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
    <description>AUC (0-144) is defined as AUC from time 0 to 144 hours postdose, calculated by linear-linear trapezoidal summation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Analyte Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC [0-last])</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>AUC (0-last) is defined as AUC from time 0 to the time of the last measurable (non-below quantification limit [non-BQL]) concentration, calculated by linear-linear trapezoidal summation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Analyte Concentration-time Curve From Time Zero to Infinity (AUC [0-infinity])</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>AUC (0-infinity) is defined as AUC from time 0 to infinity, calculated as the sum of AUC (0-last) and C(last)/lambda(z); where C(last) is the last observed measurable (non-BQL) concentration; and lambda(z) is apparent terminal elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Apparent Oral Clearance (CL/F)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>CL/F is defined as total apparent oral clearance, calculated as dose/AUC (0-infinity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Vd/F is defined as apparent volume of distribution, calculated as dose/[lambda (z)*AUC (0-infinity)].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (Lambda[z])</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Lambda(z) is defined as apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log-transformed concentration vs time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>t1/2 is defined as apparent terminal elimination half-life, calculated as 0.693/lambda(z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of JNJ-56136379 Excreted in Urine (Ae,%Dose)</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Ae,%Dose is defined as cumulative urinary recovery represented as a percentage of dose, calculated as 100*(Aetotal/Dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr)</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
    <description>CLr is defined as renal clearance, calculated as Ae(0-144h)/AUC(144h).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe renal impairment or end stage renal disease (ESRD) and not on hemodialysis (estimated glomerular filtration rate [eGFR] less than [&lt;] 30 milliliter/minute/1.73 meter square [mL/min/1.73m^2]) will receive a single oral dose of JNJ-56136379.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy participants with normal renal function (eGFR greater than or equal to [&gt;=] 90 mL/min/1.73m^2), will receive a single oral dose of JNJ-56136379.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 3 (Optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild renal impairment (eGFR: 60 to 89 mL/min/1.73m^2) will receive a single oral dose of JNJ-56136379.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 4 (Optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate renal impairment (eGFR: 30 to 59 mL/min/1.73m^2) will receive a single oral dose of JNJ-56136379.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 5 (Optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with ESRD requiring hemodialysis (eGFR: &lt;15 mL/min/1.73m^2) will receive a single oral dose of JNJ-56136379.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-56136379</intervention_name>
    <description>Participants will receive JNJ-56136379 tablets orally.</description>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3 (Optional)</arm_group_label>
    <arm_group_label>Part B: Group 4 (Optional)</arm_group_label>
    <arm_group_label>Part B: Group 5 (Optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Body mass index (BMI) (weight [kg]/height [m]^2) between 18.0 and 36.0 kilogram/meter^2
        (kg/m2) (inclusive), and body weight not less than (&lt;) 50 kg

        Participants with normal renal function:

          -  Have normal renal function defined as estimated glomerular filtration rate (eGFR)
             greater than or equal to (&gt;=) 90 milliliter/minute/1.73 meter square (mL/min/1.73m^2)

          -  Must have stable renal function as defined as: (a) for participants with impaired
             renal function: &lt;20 percent (%) change in serum creatinine concentrations between
             screening and Day -1; (b) for healthy participants: a change in serum creatinine
             concentration &lt;0.2 milligram per deciliter (mg/dL) between screening and Day -1

        Participants with renal impairment:

          -  Have an impaired renal function based on eGFR as given below: (a) eGFR &lt;90 to 60
             mL/min/1.73m^2 for participants in the mild renal impairment cohort; (b) eGFR 30 to 59
             mL/min/1.73m^2 for participants in the moderate impairment cohort; (c) eGFR &lt;30
             mL/min/1.73m^2 for participants with severe renal impairment or end stage renal
             disease (ESRD) and not on hemodialysis; (d) eGFR &lt;15 mL/min/1.73m2 for participants
             with ESRD requiring hemodialysis

          -  Concomitant medications to treat underlying disease states or medical conditions
             related to renal impairment are allowed. Participants must be on a stable dose of
             medication and/or treatment regimen for at least 2 months before dosing as well as
             during the study

        Exclusion Criteria:

        - Individuals who take creatine supplements, have a non-standard muscle mass such as
        amputation, malnutrition, or muscle wasting; because these factors are not accounted for in
        the prediction equations for GFR chronic kidney disease epidemiology collaboration (CKD
        EPI)

        Participants with normal renal function:

          -  Clinically significant abnormal values for hematology, clinical chemistry, or
             urinalysis at screening or Day -1, as deemed appropriate by the investigator

          -  Clinically significant abnormal physical examination, vital signs, body temperature,
             or 12 lead ECG at screening or Day -1, as deemed appropriate by the investigator

        Participants with renal impairment:

          -  Evidence of clinically apparent concurrent disease based upon complete clinical
             laboratory testing, full physical examination, or medical history, except for
             controlled hypertension and those problems directly associated with the primary
             diagnosis of renal impairment

          -  Any clinically significant laboratory abnormality except abnormalities that may be
             caused by renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

